|
1
|
Goldstone AH, Richards SM, Lazarus HM,
Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH,
Foroni L, et al: In adults with standard-risk acute lymphoblastic
leukemia, the greatest benefit is achieved from a matched sibling
allogeneic transplantation in first complete remission and an
autologous transplantation is less effective than conventional
consolidation/maintenance chemotherapy in all patients: Final
results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
Blood. 111:1827–1833. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pui CH, Sandlund JT, Pei D, Campana D,
Rivera GK, Ribeiro RC, Rubnitz JE, Razzouk BI, Howard SC, Hudson
MM, et al: Improved outcome for children with acute lymphoblastic
leukemia: Results of total therapy study XIIIB at St Jude
children's research hospital. Blood. 104:2690–2696. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bassan R: Evolving strategies for the
management of high-risk adult acute lymphoblastic leukemia.
Haematologica. 90:12992005.PubMed/NCBI
|
|
4
|
Frey NV and Porter DL: CAR T-cells merge
into the fast lane of cancer care. Am J Hematol. 91:146–150. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Park JH, Geyer MB and Brentjens RJ:
CD19-targeted CAR T-cell therapeutics for hematologic malignancies:
Interpreting clinical outcomes to date. Blood. 127:3312–3320. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schreiber-Agus N and DePinho RA:
Repression by the Mad(Mxi1)-Sin3 complex. Bioessays. 20:808–818.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou F, Medh RD and Thompson EB:
Glucocorticoid mediated transcriptional repression of c-myc in
apoptotic human leukemic CEM cells. J Steroid Biochem Mol Biol.
73:195–202. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ge Z, Guo X, Li J, Hartman M, Kawasawa YI,
Dovat S and Song C: Clinical significance of high c-MYC and low
MYCBP2 expression and their association with Ikaros dysfunction in
adult acute lymphoblastic leukemia. Oncotarget. 6:42300–42311.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roderick JE, Tesell J, Shultz LD, Brehm
MA, Greiner DL, Harris MH, Silverman LB, Sallan SE, Gutierrez A,
Look AT, et al: c-Myc inhibition prevents leukemia initiation in
mice and impairs the growth of relapsed and induction failure
pediatric T-ALL cells. Blood. 123:1040–1050. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gaynon PS and Carrel AL:
Glucocorticosteroid therapy in childhood acute lymphoblastic
leukemia. Adv Exp Med Biol. 457:593–605. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Distelhorst CW: Recent insights into the
mechanism of glucocorticosteroid-induced apoptosis. Cell Death
Differ. 9:6–19. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tissing WJ, Meijerink JP, den Boer ML and
Pieters R: Molecular determinants of glucocorticoid sensitivity and
resistance in acute lymphoblastic leukemia. Leukemia. 17:17–25.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saffar AS, Ashdown H and Gounni AS: The
molecular mechanisms of glucocorticoids-mediated neutrophil
survival. Curr Drug Targets. 12:556–562. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thulasi R, Harbour DV and Thompson EB:
Suppression of c-myc is a critical step in glucocorticoid-induced
human leukemic cell lysis. J Biol Chem. 268:18306–18312.
1993.PubMed/NCBI
|
|
15
|
Helmberg A, Auphan N, Caelles C and Karin
M: Glucocorticoid-induced apoptosis of human leukemic cells is
caused by the repressive function of the glucocorticoid receptor.
EMBO J. 14:452–460. 1995.PubMed/NCBI
|
|
16
|
Mu Q, Ma Q, Lu S, Zhang T, Yu M, Huang X,
Chen J and Jin J: 10058-F4, a c-Myc inhibitor, markedly increases
valproic acid-induced cell death in Jurkat and CCRF-CEM
T-lymphoblastic leukemia cells. Oncol Lett. 8:1355–1359. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang MJ, Cheng YC, Liu CR, Lin S and Liu
HE: A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle
arrest, apoptosis, and myeloid differentiation of human acute
myeloid leukemia. Exp Hematol. 34:1480–1489. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Holien T, Våtsveen TK, Hella H, Rampa C,
Brede G, Groseth LA, Rekvig M, Borset M, Standal T, Waage A and
Sundan A: Bone morphogenetic proteins induce apoptosis in multiple
myeloma cells by Smad-dependent repression of MYC. Leukemia.
26:1073–1080. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luscher B and Larsson LG: The basic
region/helix-loop-helix/leucine zipper domain of Myc
proto-oncoproteins: Function and regulation. Oncogene.
18:2955–2966. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weng AP, Ferrando AA, Lee W, Morris JP IV,
Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT and Aster
JC: Activating mutations of NOTCH1 in human T cell acute
lymphoblastic leukemia. Science. 306:269–271. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
O'Neil J, Grim J, Strack P, Rao S,
Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters
R, et al: FBW7 mutations in leukemic cells mediate NOTCH pathway
activation and resistance to gamma-secretase inhibitors. J Exp Med.
204:1813–1824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yin X, Giap C, Lazo JS and Prochownik EV:
Low molecular weight inhibitors of Myc-Max interaction and
function. Oncogene. 22:6151–6159. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ott CJ, Kopp N, Bird L, Paranal RM, Qi J,
Bowman T, Rodig SJ, Kung AL, Bradner JE and Weinstock DM: BET
bromodomain inhibition targets both c-Myc and IL7R in high-risk
acute lymphoblastic leukemia. Blood. 120:2843–2852. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mateyak MK, Obaya AJ and Sedivy JM: c-Myc
regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle
progression at multiple independent points. Mol Cell Biol.
19:4672–4683. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hermeking H, Rago C, Schuhmacher M, Li Q,
Barrett JF, Obaya AJ, O'Connell BC, Mateyak MK, Tam W, Kohlhuber F,
et al: Identification of CDK4 as a target of c-MYC. Proc Natl Acad
Sci USA. 97:2229–2234. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pikman Y, Alexe G, Roti G, Conway AS,
Furman A, Lee ES, Place AE, Kim S, Saran C, Modiste R, et al:
Synergistic drug combinations with a CDK4/6 inhibitor in T-cell
acute lymphoblastic leukemia. Clin Cancer Res. 23:1012–1024. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Y, Ge J, Li Q, Guo X, Gu L, Ma ZG, Li
XH and Zhu YP: Low-dose anisomycin sensitizes
glucocorticoid-resistant T-acute lymphoblastic leukemia CEM-C1
cells to dexamethasone-induced apoptosis through activation of
glucocorticoid receptor and p38-MAPK/JNK. Leuk Lymphoma.
55:2179–2188. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Samon JB, Castillo-Martin M, Hadler M,
Ambesi-Impiobato A, Paietta E, Racevskis J, Wiernik PH, Rowe JM,
Jakubczak J, Randolph S, et al: Preclinical analysis of the
γ-secretase inhibitor PF-03084014 in combination with
glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer
Ther. 11:1565–1575. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Prochownik EV and Vogt PK: Therapeutic
targeting of Myc. Genes Cancer. 1:650–659. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo J, Parise RA, Joseph E, Egorin MJ,
Lazo JS, Prochownik EV and Eiseman JL: Efficacy, pharmacokinetics,
tisssue distribution, and metabolism of the Myc-Max disruptor,
10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in
mice. Cancer Chemother Pharmacol. 63:615–625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Soodgupta D, Pan D, Cui G, Senpan A, Yang
X, Lu L, Weilbaecher KN, Prochownik EV, Lanza GM and Tomasson MH:
Small molecule MYC inhibitor conjugated to integrin-targeted
nanoparticles extends survival in a mouse model of disseminated
multiple myeloma. Mol Cancer Ther. 14:1286–1294. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Abraham SA, Hopcroft LE, Carrick E, Drotar
ME, Dunn K, Williamson AJ, Korfi K, Baquero P, Park LE, Scott MT,
et al: Dual targeting of p53 and c-MYC selectively eliminates
leukaemic stem cells. Nature. 534:341–346. 2016. View Article : Google Scholar : PubMed/NCBI
|
